» Articles » PMID: 37581180

What is the Significance of a Faecal Elastase-1 Level Between 200 and 500μg/g?

Overview
Specialty Gastroenterology
Date 2023 Aug 15
PMID 37581180
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Pancreatic exocrine insufficiency is a cause of malabsorption. It is generally diagnosed if faecal elastase-1 (FE-1) levels are below 200 µg/g. Pancreatic function is assumed to be normal when faecal elastase levels are >500 µg/g. The significance of faecal elastase levels above 200 µg/g but less than 500 µg/g is unclear.

Methods: This retrospective study reports the response to treatment in patients who had an FE-1 level between 200 and 500 µg/g.

Results: Of these 82 patients, 28 were offered pancreatic enzyme replacement therapy (PERT). A clinical response, defined as an improvement in their initial symptoms after commencing PERT, was seen in 20 patients (71%), 7 with potentially predisposing conditions and 13 with functional diarrhoea. PERT particularly abolished or improved diarrhoea, steatorrhoea and flatulence.

Conclusion: Clinicians should, therefore, be aware that a trial of PERT given to patients with FE-1 levels between 200 and 500 µg/g may lead to improvement in gastrointestinal symptoms.

Citing Articles

Crohn's Disease-Associated Granulomatous Pancreatitis With Exocrine Pancreatic Insufficiency.

Xu A, Vincent S, Ma S, Catania V, Zarrin-Khameh N ACG Case Rep J. 2024; 11(8):e01428.

PMID: 39081299 PMC: 11286247. DOI: 10.14309/crj.0000000000001428.

References
1.
Hardt P, Hauenschild A, Nalop J, Marzeion A, Jaeger C, Teichmann J . High prevalence of exocrine pancreatic insufficiency in diabetes mellitus. A multicenter study screening fecal elastase 1 concentrations in 1,021 diabetic patients. Pancreatology. 2003; 3(5):395-402. DOI: 10.1159/000073655. View

2.
Maconi G, Dominici R, Molteni M, Ardizzone S, Bosani M, Ferrara E . Prevalence of pancreatic insufficiency in inflammatory bowel diseases. Assessment by fecal elastase-1. Dig Dis Sci. 2007; 53(1):262-70. DOI: 10.1007/s10620-007-9852-y. View

3.
Saito T, Hirano K, Isayama H, Nakai Y, Saito K, Umefune G . The Role of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer: A Prospective Cohort Study. Pancreas. 2017; 46(3):341-346. DOI: 10.1097/MPA.0000000000000767. View

4.
Leeds J, Hopper A, Hurlstone D, Edwards S, McAlindon M, Lobo A . Is exocrine pancreatic insufficiency in adult coeliac disease a cause of persisting symptoms?. Aliment Pharmacol Ther. 2007; 25(3):265-71. DOI: 10.1111/j.1365-2036.2006.03206.x. View

5.
Abdulkarim A, Burgart L, See J, Murray J . Etiology of nonresponsive celiac disease: results of a systematic approach. Am J Gastroenterol. 2002; 97(8):2016-21. DOI: 10.1111/j.1572-0241.2002.05917.x. View